Evidence map›Paper›PMID 42539561›Full record

ArticlePathology oncology research : POR2026

TRK immunohistochemistry in pediatric rhabdomyosarcomas: diagnostic and prognostic utility and limitations.

Renáta Lajti, Katalin Dezső, Zoltán Sápi, Gergő Papp, Anna Mohás, Bence Bukovszky, Sándor Szabó, Luca Felkai, Monika Csóka

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology oncology research : POR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Renáta LajtiPediatric Center Tűzoltó Street Department, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
Katalin DezsőDepartment of Pathology and Experimental Cancer Research, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
Zoltán SápiDepartment of Pathology and Experimental Cancer Research, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
Gergő PappDepartment of Pathology and Experimental Cancer Research, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
Anna MohásPediatric Center Tűzoltó Street Department, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
Bence BukovszkyPediatric Center Tűzoltó Street Department, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
Sándor SzabóPediatric Center Tűzoltó Street Department, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
Luca FelkaiPediatric Center Tűzoltó Street Department, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
Monika CsókaPediatric Center Tűzoltó Street Department, Faculty of Medicine, Semmelweis University, Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rhabdomyosarcoma is the third most common extracranial solid tumor in childhood. Treatment of patients is multimodal, based on systemic chemotherapy and local therapy by surgery and/or radiotherapy. Although standard therapies result in an overall survival of more than 75% for patients in the low-risk group, the prognosis for high-risk patients remains poor. For this reason, new therapeutic alternatives are needed. One such option is the use of specific Tropomyosin receptor kinase (TRK) inhibitors, which provides the opportunity of targeted therapeutic treatment for patients carrying

Indexed as

Biomarkers, TumorReceptor Protein-Tyrosine KinasesReceptor, trkARhabdomyosarcomaAdolescentChildChild, PreschoolFemaleHumansImmunohistochemistryInfantMalePrognosisBiomarkers, TumorReceptor Protein-Tyrosine KinasesReceptor, trkAimmunohistochemistryNTRKrhabdomyosarcomasoft tissue sarcomatargeted therapy

Identifiers

PMID42539561
PMCPMC13423737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.